Spyre Therapeutics
SYRE
SYRE
55 hedge funds and large institutions have $22.6M invested in Spyre Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
73% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 15
Holders
55
Holding in Top 10
1
Calls
$8K
Puts
–
Top Buyers
| 1 | +$180K | |
| 2 | +$154K | |
| 3 | +$93.9K | |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$39.5K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$28.9K |
Top Sellers
| 1 | -$1.43M | |
| 2 | -$1.24M | |
| 3 | -$255K | |
| 4 |
D.E. Shaw & Co
New York
|
-$241K |
| 5 |
Renaissance Technologies
New York
|
-$174K |